抗血管内皮生长因子治疗新生血管性老年黄斑变性和糖尿病性黄斑水肿的患者偏好:多国离散选择实验研究》。

IF 2 4区 医学 Q2 OPHTHALMOLOGY
Ophthalmic Research Pub Date : 2025-01-01 Epub Date: 2024-11-21 DOI:10.1159/000541349
Alfredo García-Layana, Gloria C Chi, Laurent Kodjikian, Mariacristina Parravano, David Chow, Timothy L Jackson, Carl Danzig, Liliana P Paris, Mirela Mirt, Mickael Henry-Szatkowski, Hannah B Lewis, Brittany Gentile
{"title":"抗血管内皮生长因子治疗新生血管性老年黄斑变性和糖尿病性黄斑水肿的患者偏好:多国离散选择实验研究》。","authors":"Alfredo García-Layana, Gloria C Chi, Laurent Kodjikian, Mariacristina Parravano, David Chow, Timothy L Jackson, Carl Danzig, Liliana P Paris, Mirela Mirt, Mickael Henry-Szatkowski, Hannah B Lewis, Brittany Gentile","doi":"10.1159/000541349","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>New anti-vascular endothelial growth factor (VEGF) treatments are emerging for the treatment of diabetic macular edema (DME)/neovascular age-related macular degeneration (nAMD). This study aimed to explore the treatment attributes patients find important when deciding on treatment options.</p><p><strong>Methods: </strong>This noninterventional survey study assessed treatment preferences through a discrete choice experiment (DCE) among patients with DME/nAMD in the USA, Canada, France, Italy, Spain, and the UK. The DCE design was informed by a targeted literature review and qualitative interview research and included five treatment attributes: mode of administration, frequency of examinations, frequency of injections or refills, likely change in visual acuity, and eye-related side effects. Conditional logit models were used to analyze the choice data.</p><p><strong>Results: </strong>Overall, 537 patients completed the DCE (DME, n = 173; nAMD, n = 364). Patients reported preferring \"injection\" over \"implant surgery and refills\" and better visual outcomes over \"stabilization,\" which were also the most important attributes driving preference (35.1% and 31.5%, respectively). They also showed a preference for less-frequent treatment and examinations and for \"mild-moderate, frequent\" over \"severe, rare\" side effects. These findings were generally consistent across the two conditions, although significant differences were found depending on anti-VEGF treatment duration (nAMD, DME) and number of reported barriers (nAMD).</p><p><strong>Conclusion: </strong>Patient preferences for treatment are driven by several factors. Considering these preferences is essential when designing/introducing new therapies. Individual treatment preferences should be identified and given key consideration when helping patients select from an expanding array of treatment options.</p>","PeriodicalId":19662,"journal":{"name":"Ophthalmic Research","volume":" ","pages":"13-22"},"PeriodicalIF":2.0000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Patient Preferences with Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Multinational Discrete Choice Experiment Study.\",\"authors\":\"Alfredo García-Layana, Gloria C Chi, Laurent Kodjikian, Mariacristina Parravano, David Chow, Timothy L Jackson, Carl Danzig, Liliana P Paris, Mirela Mirt, Mickael Henry-Szatkowski, Hannah B Lewis, Brittany Gentile\",\"doi\":\"10.1159/000541349\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Introduction: </strong>New anti-vascular endothelial growth factor (VEGF) treatments are emerging for the treatment of diabetic macular edema (DME)/neovascular age-related macular degeneration (nAMD). This study aimed to explore the treatment attributes patients find important when deciding on treatment options.</p><p><strong>Methods: </strong>This noninterventional survey study assessed treatment preferences through a discrete choice experiment (DCE) among patients with DME/nAMD in the USA, Canada, France, Italy, Spain, and the UK. The DCE design was informed by a targeted literature review and qualitative interview research and included five treatment attributes: mode of administration, frequency of examinations, frequency of injections or refills, likely change in visual acuity, and eye-related side effects. Conditional logit models were used to analyze the choice data.</p><p><strong>Results: </strong>Overall, 537 patients completed the DCE (DME, n = 173; nAMD, n = 364). Patients reported preferring \\\"injection\\\" over \\\"implant surgery and refills\\\" and better visual outcomes over \\\"stabilization,\\\" which were also the most important attributes driving preference (35.1% and 31.5%, respectively). They also showed a preference for less-frequent treatment and examinations and for \\\"mild-moderate, frequent\\\" over \\\"severe, rare\\\" side effects. These findings were generally consistent across the two conditions, although significant differences were found depending on anti-VEGF treatment duration (nAMD, DME) and number of reported barriers (nAMD).</p><p><strong>Conclusion: </strong>Patient preferences for treatment are driven by several factors. Considering these preferences is essential when designing/introducing new therapies. Individual treatment preferences should be identified and given key consideration when helping patients select from an expanding array of treatment options.</p>\",\"PeriodicalId\":19662,\"journal\":{\"name\":\"Ophthalmic Research\",\"volume\":\" \",\"pages\":\"13-22\"},\"PeriodicalIF\":2.0000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ophthalmic Research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1159/000541349\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/11/21 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"OPHTHALMOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmic Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000541349","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/21 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

导言:抗血管内皮生长因子(VEGF)治疗糖尿病黄斑水肿(DME)/新生血管性老年黄斑变性(nAMD)的新疗法不断涌现。本研究旨在探讨患者在决定治疗方案时认为重要的治疗属性:这项非常规调查研究通过离散选择实验(DCE)对美国、加拿大、法国、意大利、西班牙和英国的 DME/nAMD 患者的治疗偏好进行了评估。离散选择实验的设计参考了有针对性的文献综述和定性访谈研究,包括五个治疗属性:给药方式、检查频率、注射或补药频率、视力可能的变化以及与眼睛相关的副作用。我们使用条件对数模型对选择数据进行了分析:共有 537 名患者完成了 DCE(DME,n = 173;nAMD,n = 364)。患者表示,与 "植入手术和补液 "相比,他们更喜欢 "注射",与 "稳定 "相比,他们更喜欢更好的视觉效果,这也是促使他们做出选择的最重要因素(分别为 35.1% 和 31.5%)。此外,他们还倾向于治疗和检查频率较低,以及 "轻度-中度、频繁 "而非 "严重、罕见 "的副作用。尽管抗血管内皮生长因子治疗的持续时间(nAMD、DME)和报告的障碍数量(nAMD)存在显著差异,但这些结果在两种情况下基本一致:结论:患者对治疗的偏好受多种因素的影响。在设计/引入新疗法时,考虑这些因素至关重要。在帮助患者从越来越多的治疗方案中进行选择时,应识别并重点考虑个人的治疗偏好。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Patient Preferences with Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Multinational Discrete Choice Experiment Study.

Introduction: New anti-vascular endothelial growth factor (VEGF) treatments are emerging for the treatment of diabetic macular edema (DME)/neovascular age-related macular degeneration (nAMD). This study aimed to explore the treatment attributes patients find important when deciding on treatment options.

Methods: This noninterventional survey study assessed treatment preferences through a discrete choice experiment (DCE) among patients with DME/nAMD in the USA, Canada, France, Italy, Spain, and the UK. The DCE design was informed by a targeted literature review and qualitative interview research and included five treatment attributes: mode of administration, frequency of examinations, frequency of injections or refills, likely change in visual acuity, and eye-related side effects. Conditional logit models were used to analyze the choice data.

Results: Overall, 537 patients completed the DCE (DME, n = 173; nAMD, n = 364). Patients reported preferring "injection" over "implant surgery and refills" and better visual outcomes over "stabilization," which were also the most important attributes driving preference (35.1% and 31.5%, respectively). They also showed a preference for less-frequent treatment and examinations and for "mild-moderate, frequent" over "severe, rare" side effects. These findings were generally consistent across the two conditions, although significant differences were found depending on anti-VEGF treatment duration (nAMD, DME) and number of reported barriers (nAMD).

Conclusion: Patient preferences for treatment are driven by several factors. Considering these preferences is essential when designing/introducing new therapies. Individual treatment preferences should be identified and given key consideration when helping patients select from an expanding array of treatment options.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Ophthalmic Research
Ophthalmic Research 医学-眼科学
CiteScore
3.80
自引率
4.80%
发文量
75
审稿时长
6-12 weeks
期刊介绍: ''Ophthalmic Research'' features original papers and reviews reporting on translational and clinical studies. Authors from throughout the world cover research topics on every field in connection with physical, physiologic, pharmacological, biochemical and molecular biological aspects of ophthalmology. This journal also aims to provide a record of international clinical research for both researchers and clinicians in ophthalmology. Finally, the transfer of information from fundamental research to clinical research and clinical practice is particularly welcome.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信